JP2017501200A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501200A5 JP2017501200A5 JP2016544111A JP2016544111A JP2017501200A5 JP 2017501200 A5 JP2017501200 A5 JP 2017501200A5 JP 2016544111 A JP2016544111 A JP 2016544111A JP 2016544111 A JP2016544111 A JP 2016544111A JP 2017501200 A5 JP2017501200 A5 JP 2017501200A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- pharmaceutical composition
- disease
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 7
- 239000002955 immunomodulating agent Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 229940000425 combination drug Drugs 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 238000002619 cancer immunotherapy Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- -1 3-dihydroindolinyl Chemical group 0.000 description 15
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN6/DEL/2014 | 2014-01-01 | ||
| IN6DE2014 | 2014-01-01 | ||
| PCT/US2014/072922 WO2015103355A1 (en) | 2014-01-01 | 2014-12-31 | Compounds and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000208A Division JP2019048899A (ja) | 2014-01-01 | 2019-01-04 | 化合物及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501200A JP2017501200A (ja) | 2017-01-12 |
| JP2017501200A5 true JP2017501200A5 (enExample) | 2019-02-14 |
| JP6474166B2 JP6474166B2 (ja) | 2019-02-27 |
Family
ID=52293317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544111A Expired - Fee Related JP6474166B2 (ja) | 2014-01-01 | 2014-12-31 | 化合物及び使用方法 |
| JP2019000208A Pending JP2019048899A (ja) | 2014-01-01 | 2019-01-04 | 化合物及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000208A Pending JP2019048899A (ja) | 2014-01-01 | 2019-01-04 | 化合物及び使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10030004B2 (enExample) |
| EP (1) | EP3089971B1 (enExample) |
| JP (2) | JP6474166B2 (enExample) |
| CN (2) | CN106132950B (enExample) |
| AU (2) | AU2014373773C1 (enExample) |
| CA (1) | CA2935392C (enExample) |
| CY (1) | CY1123290T1 (enExample) |
| DK (1) | DK3089971T3 (enExample) |
| ES (1) | ES2813875T3 (enExample) |
| HR (1) | HRP20201384T1 (enExample) |
| HU (1) | HUE050761T2 (enExample) |
| LT (1) | LT3089971T (enExample) |
| PL (1) | PL3089971T3 (enExample) |
| PT (1) | PT3089971T (enExample) |
| RS (1) | RS60718B1 (enExample) |
| SI (1) | SI3089971T1 (enExample) |
| WO (1) | WO2015103355A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3089971T (lt) | 2014-01-01 | 2020-10-12 | Medivation Technologies Llc | Junginiai ir panaudojimo būdai |
| JP6952747B2 (ja) | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ |
| WO2020090705A1 (ja) | 2018-10-31 | 2020-05-07 | 千寿製薬株式会社 | 網膜神経節細胞死抑制剤 |
| PE20211756A1 (es) * | 2018-12-20 | 2021-09-07 | Pfizer | FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß |
| CN113348167A (zh) * | 2018-12-27 | 2021-09-03 | 奈可萨斯医药有限公司 | 用于治疗癌症的作为TGF-βR1(ALK5)抑制剂的(吡啶-2-基)胺衍生物 |
| EP4041399A1 (en) | 2019-10-02 | 2022-08-17 | Tolremo Therapeutics AG | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| CN111116565B (zh) * | 2020-04-01 | 2020-07-14 | 中科利健制药(广州)有限公司 | 2-芳基-4-（4-吡唑氧基）吡啶类化合物、其制备方法、药物组合物与应用 |
| BR112022026045A2 (pt) * | 2020-06-25 | 2023-01-17 | Tolremo Therapeutics Ag | Derivados heterocíclicos, composições farmacêutucas e seu uso no tratamento, melhora ou prevenção de doença fibrótica |
| KR20230028798A (ko) | 2020-06-25 | 2023-03-02 | 톨레모 테라퓨틱스 아게 | 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물 |
| SI4182308T1 (sl) * | 2020-07-15 | 2025-04-30 | Chiesi Farmaceutici S.P.A. | Piridazinil amino derivati kot zaviralci alk5 |
| CN114369083A (zh) * | 2020-10-15 | 2022-04-19 | 四川科伦博泰生物医药股份有限公司 | 杂环类化合物、包含其的药物组合物、其制备方法及其用途 |
| WO2022115384A1 (en) * | 2020-11-24 | 2022-06-02 | Aligos Therapeutics, Inc. | Tricyclic compounds |
| WO2022130206A1 (en) | 2020-12-16 | 2022-06-23 | Pfizer Inc. | TGFβr1 INHIBITOR COMBINATION THERAPIES |
| CN112843058A (zh) * | 2021-01-27 | 2021-05-28 | 复旦大学附属华山医院 | 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用 |
| WO2022229846A1 (en) | 2021-04-29 | 2022-11-03 | Pfizer Inc. | Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor |
| CN118103387A (zh) | 2021-09-30 | 2024-05-28 | 肽梦想株式会社 | 肽 |
| CN115353326A (zh) * | 2022-07-27 | 2022-11-18 | 魏玉芝 | 一种反光防车印沥青及其制备方法 |
| CN116606244A (zh) * | 2023-05-26 | 2023-08-18 | 康化（上海）新药研发有限公司 | 一种6-溴-5-甲氧基吡啶-3-胺的合成方法 |
| CN117865965B (zh) * | 2024-01-08 | 2024-06-28 | 贵州省天然产物研究中心 | 吡咯并嘧啶-4-胺和吡唑并嘧啶-4-胺衍生物及制备方法和应用 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| DE69408750T2 (de) | 1993-08-26 | 1998-07-23 | Ono Pharmaceutical Co | 4-Aminopyrimidin Derivate |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| WO2000047102A2 (en) | 1999-02-11 | 2000-08-17 | The General Hospital Corporation | COMPOSITIONS AND METHODS FOR MODULATING TGF-β SIGNALING |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CA2432799C (en) | 2000-12-21 | 2008-08-19 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20050009815A1 (en) | 2001-11-27 | 2005-01-13 | Devita Robert J. | 4-Aminoquinoline compounds |
| US20040006030A1 (en) | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of TGF-beta 2 expression |
| US20030225089A1 (en) | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| AU2003229305A1 (en) | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| US20040146509A1 (en) | 2002-07-25 | 2004-07-29 | Zhihe Li | Methods for improvement of lung function using TGF-beta inhibitors |
| CA2498460A1 (en) | 2002-09-10 | 2004-03-25 | Scios Inc. | Inhibitors of tfg.beta. |
| PL375975A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors |
| KR20050057393A (ko) | 2002-09-18 | 2005-06-16 | 화이자 프로덕츠 인크. | 전환 성장 인자 (ｔｇｆ) 억제제로서 트리아졸 유도체 |
| MXPA05002378A (es) | 2002-09-18 | 2005-05-23 | Pfizer Prod Inc | Nuevos compuestos de isotiazol e isoxazol como inhibidores del fctor de crecimiento transformador (tgf). |
| EP1542684B1 (en) | 2002-09-18 | 2009-12-02 | Pfizer Products Inc. | Novel pyrazole compounds as transforming growth factor (tgf) inhibitors |
| CA2498047C (en) | 2002-09-18 | 2009-05-19 | Pfizer Products Inc. | Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
| CA2506978A1 (en) | 2002-11-22 | 2004-06-10 | Scios, Inc. | Method for counteracting a pathologic change in the b-adrenergic pathway |
| US20040138188A1 (en) | 2002-11-22 | 2004-07-15 | Higgins Linda S. | Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors |
| AU2003297460A1 (en) | 2002-12-19 | 2004-07-14 | Scios, Inc. | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS |
| EP1581222A2 (en) | 2003-01-02 | 2005-10-05 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; |
| WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| DE602004015429D1 (de) | 2003-03-11 | 2008-09-11 | Pfizer Prod Inc | Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf) |
| EP1603908B1 (en) | 2003-03-12 | 2008-06-11 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as tgf-beta inhibitors |
| JP2006521398A (ja) | 2003-03-28 | 2006-09-21 | サイオス・インコーポレーテツド | ＴＧＦβの二−環式ピリミジン阻害剤 |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| US6875781B2 (en) * | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
| WO2004112710A2 (en) | 2003-06-17 | 2004-12-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß |
| CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
| TW200510373A (en) | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
| EP1648520B1 (en) | 2003-07-16 | 2010-05-05 | RVX Therapeutics, Inc. | Compounds and methods for downregulating the effects of tgf-beta |
| US20050026933A1 (en) | 2003-08-01 | 2005-02-03 | Wyeth Holdings Corporation | Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| WO2005032481A2 (en) | 2003-09-30 | 2005-04-14 | Scios Inc. | Quinazoline derivatives as medicaments |
| US7390907B2 (en) | 2003-09-30 | 2008-06-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP1677734B1 (en) | 2003-10-15 | 2016-04-20 | National Jewish Health | Cystatin c as an antagonist of tgf-b and methods related thereto |
| AU2004289518A1 (en) | 2003-11-10 | 2005-05-26 | Merck Sharp & Dohme Limited | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
| AR046324A1 (es) | 2003-11-10 | 2005-11-30 | Merck Sharp & Dohme | Heterociclos nitrogenados de seis miembros aminosustituidos que contienen sustituyentes de quinolina o isoquinolina |
| AU2004292546A1 (en) | 2003-11-21 | 2005-06-09 | Merck & Co., Inc. | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain |
| KR20070007055A (ko) * | 2003-12-24 | 2007-01-12 | 사이오스 인코퍼레이티드 | Ｔｇｆ-베타 억제제를 이용한 악성 신경교종의 치료법 |
| WO2005069935A2 (en) | 2004-01-20 | 2005-08-04 | University Of Medicine And Dentistry Of New Jersey | METHODS FOR MEASURING TRANSFORMING GROWTH FACTOR BETA (TGF-β) RECEPTOR SIGNALING ACTIVITY AND USES THEREOF |
| WO2005092894A1 (en) | 2004-03-01 | 2005-10-06 | Eli Lilly And Company | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms |
| AU2005289426A1 (en) * | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| AU2005288858B2 (en) | 2004-09-30 | 2011-04-21 | Janssen R&D Ireland | HCV inhibiting bi-cyclic pyrimidines |
| WO2006052568A2 (en) | 2004-11-10 | 2006-05-18 | Eli Lilly And Company | Tgf-beta inhibitors |
| US7767687B2 (en) | 2004-12-13 | 2010-08-03 | Biogen Idec Ma Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| US20060217437A1 (en) | 2005-03-17 | 2006-09-28 | Burmester James K | TGF-beta modulators and methods for using the same |
| WO2006100310A1 (en) | 2005-03-25 | 2006-09-28 | Tibotec Pharmaceuticals Ltd | Heterobicylic inhibitors of hcv |
| ES2369282T3 (es) | 2005-03-25 | 2011-11-29 | Tibotec Pharmaceuticals | Inhibidores heterobicíclicos de vhc. |
| US20060281763A1 (en) | 2005-03-25 | 2006-12-14 | Axon Jonathan R | Carboxamide inhibitors of TGFbeta |
| EP1885369B1 (en) | 2005-05-04 | 2015-09-23 | Evotec AG | Fused heterocyclic compounds, and compositions and uses thereof |
| TW200716631A (en) | 2005-05-12 | 2007-05-01 | Tibotec Pharm Ltd | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof |
| CN101495142A (zh) | 2006-06-05 | 2009-07-29 | 健泰科生物技术公司 | 延长EGF或TGF-α水平升高的癌症患者的存活 |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| EP2097084B1 (en) | 2006-10-04 | 2015-01-28 | Janssen R&D Ireland | Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| WO2008077086A1 (en) | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
| GB0702871D0 (en) | 2007-02-14 | 2007-03-28 | Tcp Innovations Ltd | Improved compositions and combinations 1 |
| AU2008262291A1 (en) | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
| UY31281A1 (es) * | 2007-08-13 | 2009-03-31 | Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones. | |
| NZ624345A (en) | 2008-06-27 | 2016-07-29 | Celgene Avilomics Res Inc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US20110257208A1 (en) | 2008-11-19 | 2011-10-20 | Matthew Duncton | Compounds useful as faah modulators and uses thereof |
| EP2241565A1 (en) | 2009-01-15 | 2010-10-20 | Universität Leipzig | Aurora kinase inhibitors compounds |
| WO2010102267A2 (en) | 2009-03-06 | 2010-09-10 | Ipierian, Inc. | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells |
| US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| US20120101095A1 (en) | 2009-06-22 | 2012-04-26 | Guenter Hoelzemann | Alkoxy-thienopyrimidines as tgf-beta receptor kinase modulators |
| UA108363C2 (uk) * | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US8987301B2 (en) | 2009-11-07 | 2015-03-24 | Merck Patent Gmbh | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| WO2011101069A2 (en) | 2010-02-22 | 2011-08-25 | Merck Patent Gmbh | Hetarylaminonaphthyridines |
| WO2011146287A1 (en) * | 2010-05-20 | 2011-11-24 | Takeda Pharmaceutical Company Limited | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of alk5 |
| MY177250A (en) * | 2010-06-30 | 2020-09-10 | Fujifilm Corp | Novel nicotinamide derivative or salt thereof |
| AU2011272862A1 (en) | 2010-06-30 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
| EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
| JP2014501705A (ja) * | 2010-11-01 | 2014-01-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | Ｓｙｋ調節剤としてのベンズアミドおよびニコチンアミド |
| MX2013010163A (es) | 2011-03-09 | 2013-10-30 | Merck Patent Gmbh | Derivados de pirido[2,3-b] pirazina y sus usos terapeuticos. |
| CA2832919A1 (en) * | 2011-04-12 | 2012-10-18 | Ryan C. Holcomb | Compounds, compositions, and therapeutic uses thereof |
| WO2012166617A2 (en) * | 2011-05-27 | 2012-12-06 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| US9132281B2 (en) * | 2011-06-21 | 2015-09-15 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| ES2640911T3 (es) * | 2011-09-22 | 2017-11-07 | Merck Sharp & Dohme Corp. | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus |
| US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
| WO2013158422A1 (en) | 2012-04-17 | 2013-10-24 | E. I. Du Pont De Nemours And Company | Heterocyclic compounds for controlling invertebrate pests |
| WO2013175415A1 (en) * | 2012-05-23 | 2013-11-28 | Piramal Enterprises Limited | Substituted pyrimidine compounds and uses thereof |
| EP2863914B1 (en) * | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| BR112015013247B1 (pt) * | 2012-12-11 | 2022-07-12 | Koninklijke Philips N.V. | Aparelho auxiliar para assistir na realização da braquiterapia, sistema de braquiterapia para aplicar braquiterapia a um objeto vivo, e método auxiliar para assistir na realização da braquiterapia |
| WO2014147203A1 (en) | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| LT3089971T (lt) | 2014-01-01 | 2020-10-12 | Medivation Technologies Llc | Junginiai ir panaudojimo būdai |
| UY35935A (es) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
| TWI582083B (zh) | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
| AR103232A1 (es) | 2014-12-22 | 2017-04-26 | Bristol Myers Squibb Co | ANTAGONISTAS DE TGFbR |
| PL3322695T5 (pl) | 2016-09-21 | 2025-05-05 | Celanese International Corporation | Kompozycje acesulfamu potasowego i sposoby ich wytwarzania |
-
2014
- 2014-12-31 LT LTEP14824755.4T patent/LT3089971T/lt unknown
- 2014-12-31 CN CN201480075343.2A patent/CN106132950B/zh not_active Expired - Fee Related
- 2014-12-31 ES ES14824755T patent/ES2813875T3/es active Active
- 2014-12-31 WO PCT/US2014/072922 patent/WO2015103355A1/en not_active Ceased
- 2014-12-31 HR HRP20201384TT patent/HRP20201384T1/hr unknown
- 2014-12-31 HU HUE14824755A patent/HUE050761T2/hu unknown
- 2014-12-31 AU AU2014373773A patent/AU2014373773C1/en not_active Ceased
- 2014-12-31 CN CN201810955135.1A patent/CN109045032A/zh active Pending
- 2014-12-31 RS RS20201011A patent/RS60718B1/sr unknown
- 2014-12-31 PL PL14824755T patent/PL3089971T3/pl unknown
- 2014-12-31 US US15/109,013 patent/US10030004B2/en active Active
- 2014-12-31 CA CA2935392A patent/CA2935392C/en active Active
- 2014-12-31 DK DK14824755.4T patent/DK3089971T3/da active
- 2014-12-31 EP EP14824755.4A patent/EP3089971B1/en active Active
- 2014-12-31 SI SI201431651T patent/SI3089971T1/sl unknown
- 2014-12-31 JP JP2016544111A patent/JP6474166B2/ja not_active Expired - Fee Related
- 2014-12-31 PT PT148247554T patent/PT3089971T/pt unknown
-
2018
- 2018-03-23 US US15/933,532 patent/US10501436B2/en active Active
- 2018-12-20 AU AU2018282363A patent/AU2018282363B2/en not_active Ceased
-
2019
- 2019-01-04 JP JP2019000208A patent/JP2019048899A/ja active Pending
- 2019-10-22 US US16/659,775 patent/US11053216B2/en active Active
-
2020
- 2020-08-28 CY CY20201100809T patent/CY1123290T1/el unknown
-
2021
- 2021-05-22 US US17/327,705 patent/US11702401B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501200A5 (enExample) | ||
| ES2935633T3 (es) | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos | |
| AU2018346712B2 (en) | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | |
| JP2022058398A (ja) | Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４ | |
| BR112020025073A2 (pt) | moduladores de montagem de capsídeo da hepatite b | |
| CN116783180A (zh) | 用于降解ikzf2或ikzf4的三环配体 | |
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| JP7034162B2 (ja) | インフルエンザウイルス複製の阻害剤及びその使用 | |
| JP2019514884A5 (enExample) | ||
| CN114026072A (zh) | 治疗特发性肺纤维化的方法 | |
| JP2018536681A (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| US9932340B2 (en) | Substituted indoles | |
| ES2643340T3 (es) | Agentes para tratar y/o prevenir trastornos del sueño | |
| US20210361629A1 (en) | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | |
| BR112020018094A2 (pt) | Compostos de aminopirazina diol como inibidores de pi3k-¿ | |
| JP2016503785A5 (enExample) | ||
| JP2015172098A5 (enExample) | ||
| WO2007002051A1 (en) | Carboline derivatives and their use as inhibitors of flaviviridae infections | |
| CN102482272A (zh) | 情绪障碍治疗剂 | |
| RU2019125177A (ru) | Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение | |
| WO2015134171A1 (en) | Heteroarylamide inhibitors of tbk1 | |
| JPWO2013002365A1 (ja) | 止痒剤 | |
| RU2018117499A (ru) | Производные 6-[5-амино-6-(2-этоксиэтокси)-имидазо[4,5-b]пиридин-3-ил]никотинонитрила и их применение в качестве irak ингибиторов | |
| CA2938459A1 (en) | Antibacterial compounds | |
| JP2015521639A5 (enExample) |